Article
Company expects to report interim safety and biomarker data for Cohort 1 patients in the global phase 1/ 2 clinical trial, GALax-C, by end of 2022 Excerpt from the Press Release: PHILADELPHIA, March 10, 2022 (GLOBE NEWSWIRE) — Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central…
Read More
The device-agnostic software seamlessly integrates with hospital IT for streamlined documentation, billing and QA management all in one platform Excerpt from the Press Release: REDWOOD CITY, Calif.–(BUSINESS WIRE)–Exo (pronounced “echo”), a pioneering health information and devices company, has unveiled Exo Works™, an intelligent and intuitive point-of-care ultrasound workflow solution that enables physicians to easily document, review,…
Read More
– Results suggest that mesothelin-targeted TriKE can work alongside current standard of care and provide benefit even in the hypoxic environment of a solid tumor Excerpt from the Press Release: BRISBANE, Calif., March 9, 2022 /PRNewswire/ — GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company’s proprietary tri-specific…
Read More
3D Vector ECG Collection Device Slated for FDA 510k Submission in the Fourth Quarter of 2022 Excerpt from the Press Release: SANTA CLARA, Calif.–(BUSINESS WIRE)–HeartBeam, Inc. (NASDAQ: BEAT), a developmental stage digital healthcare company with a proprietary ECG telemedicine technology for heart attack detection, today announced it has signed a professional services agreement (the “Agreement”) with…
Read More
Excerpt from the Press Release: SAN DIEGO–(BUSINESS WIRE)–Pipeline Therapeutics, a clinical-stage biopharmaceutical company pioneering precision neuroregeneration, today reported positive clinical data from its recently completed Phase 1 clinical trial evaluating the safety and tolerability of PIPE-307 in healthy volunteers. PIPE-307, the company’s lead program for myelin restoration, is an oral, highly selective antagonist of the…
Read More
Excerpt from the Press Release: BOSTON & CLEVELAND–(BUSINESS WIRE)–PathAI, a global leader in artificial intelligence (AI)-powered technology for pathology, and Cleveland Clinic today announced a five-year strategic collaboration that will focus on leveraging PathAI’s quantitative pathology algorithms both to conduct new translational research and for use as clinical diagnostics in multiple disease areas. This collaborative effort combines…
Read More
– Molecular Intelligence Trials (MI Trials) collaboration will enhance identification of patients with NTRK fusion-positive solid tumors, including primary and metastatic CNS tumors potentially eligible for enrollment in the ongoing PBI-200-101 Phase 1/2 clinical study – Pyramid Biosciences currently developing pipeline of clinical-stage precision medicines, including its lead program PBI-200, a next-generation, highly CNS penetrant…
Read More
The Company Also Announced Immunotherapy Pioneer Dr. Michael Jensen as Founding Advisor Broad research collaboration focuses on BrainChild program, a suite of five multiplex chimeric antigen receptors (CARs) that initially targets pediatric central nervous system (CNS) malignancies with limited therapeutic options. Cellevolve will also leverage Seattle Children’s renowned Cure Factory® facility for early clinical Good…
Read More
First-in-class lysine gingipain inhibitor, atuzaginstat, has the potential to reduce the malignant progression of oral potentially malignant disorders (OPMD) In vitro study results demonstrate that PD-L1 is induced by P. gingivalis and can be blocked by atuzaginstat Atuzaginstat ready to begin a Phase 2 trial for expansion into high-risk OPMD indication; IND submission expected in…
Read More Helsinn Group and BridgeBio Pharma Announce Update to Strategic Collaboration to Develop, Manufacture and Commercialize Infigratinib in Oncology Indications in the U.S. Helsinn gains an exclusive license to commercialize infigratinib in the U.S. Excerpt from the Press Release: Lugano, Switzerland and Palo Alto, CA, March 3, 2022 – Helsinn Group (Helsinn), a fully integrated, global…
Read More